National Cannabis Prevention and Information Centre

Last updated

National Cannabis Prevention and Information Centre
AbbreviationNCPIC
Formation29 April 2008 (2008-04-29)
TypeGO
Legal statusNational centre
Location
  • Sydney, Australia
Region served
Australia
Director
Prof. Jan Copeland
Parent organisation
National Drug and Alcohol Research Centre
Staff
19
Website ncpic.org.au

The National Cannabis Prevention and Information Centre (NCPIC) was established in 2008 in response to data published in the Pfizer Australia Health Report. NDARC and NCPIC have collaborated with Pfizer Australia to assist with educating the public about cannabis. [1] Many in the Australian community are concerned that this collaboration and NCPIC involvement with GW Pharmaceutical and SATIVEX [2] places NDARC and NCPIC in a position of conflicted interests. [1] In 2016 it was announced that the Australian government would cut funding to the NCPIC at year's end. [3]

Contents

While prevalence rates have markedly reduced over the past decade, [4] cannabis is still widely used by young people, and the impacts on adolescent development remain an important issue.

The key goals of the Centre are:

Rationale

The National Cannabis Prevention and Information Centre was established in response to data published in the Pfizer Australia Health Report. NDARC and NCPIC have collaborated with Pfizer Australia to assist with educating the public about cannabis. [1] Many in the Australian community are concerned that this collaboration and NCPIC involvement with GW Pharmaceutical and SATIVEX [2] places NDARC and NCPIC in a position of conflicted interests. [1]

The NCPIC mission is to reduce the use of cannabis in Australia by preventing uptake and providing the community with evidence-based information and interventions. Despite this mission, NCPIC has been seen to publish fabricated and misleading cannabis information in the past. [5]

The Centre closed its doors after losing Commonwealth funding in December 2016. [6]

See also

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

<span class="mw-page-title-main">Harm reduction</span> Public health policies designed to lessen the negative consequences associated with human behavior

Harm reduction, or harm minimization, refers to a range of intentional practices and public health policies designed to lessen the negative social and/or physical consequences associated with various human behaviors, both legal and illegal. Harm reduction is used to decrease negative consequences of recreational drug use and sexual activity without requiring abstinence, recognizing that those unable or unwilling to stop can still make positive change to protect themselves and others.

The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department of Health and Social Care in the United Kingdom which is responsible for ensuring that medicines and medical devices work and are acceptably safe.

<span class="mw-page-title-main">Nabiximols</span> Specific cannabis extract

Nabiximols is a specific Cannabis extract that was approved in 2010 as a botanical drug in the United Kingdom. Nabiximols is sold as a mouth spray intended to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis; it was developed by the UK company GW Pharmaceuticals. In 2019, it was proposed that following application of the spray, nabiximols is washed away from the oral mucosa by the saliva flow and ingested into the stomach, with subsequent absorption from the gastro-intestinal tract. Nabiximols is a combination drug standardized in composition, formulation, and dose. Its principal active components are the cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). Each spray delivers a dose of 2.7 mg THC and 2.5 mg CBD.

Drug education is the planned provision of information, guidelines, resources, and skills relevant to living in a world where psychoactive substances are widely available and commonly used for a variety of both medical and non-medical purposes, some of which may lead to harms such as overdose, injury, infectious disease, or addiction.

<span class="mw-page-title-main">Alzheimer's Association</span> Non-profit American health organization

The Alzheimer's Association was founded by Jerome H. Stone with the help of several family members in Chicago, Illinois. Incorporated on April 10, 1980, as the Alzheimer's Disease and Related Disorders Association, Inc., it is a non-profit American volunteer health organization which focuses on care, support and research for Alzheimer's disease.

Pharmaceutical policy is a branch of health policy that deals with the development, provision and use of medications within a health care system. It embraces drugs, biologics, vaccines and natural health products.

<span class="mw-page-title-main">Lasofoxifene</span> Chemical compound

Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND). It also appears to have had a statistically significant effect of reducing breast cancer in women according to a study published in The Journal of the National Cancer Institute.

Geoffrey William Guy is a British pharmacologist, physician, businessman and academic, who co-founded GW Pharmaceuticals and has developed treatments using compounds found in cannabis, which are the first cannabis-based medicines approved by and available on the British National Health Service (NHS).

The history of HIV/AIDS in Australia is distinctive, as Australian government bodies recognised and responded to the AIDS pandemic relatively swiftly, with the implementation of effective disease prevention and public health programs, such as needle and syringe programs (NSPs). As a result, despite significant numbers of at-risk group members contracting the virus in the early period following its discovery, Australia achieved and has maintained a low rate of HIV infection in comparison to the rest of the world.

Illicit drug use in Australia is the recreational use of prohibited drugs in Australia. Illicit drugs include illegal drugs, pharmaceutical drugs when used for non-medical purposes, and other substances used inappropriately. According to government and community organisations, the use and abuse, and the illegality, of illicit drugs is a social, health and legal issue that creates an annual illegal market estimated to be worth A$6.7 billion. Estimates made in 2022 place the figure at A$11.3 billion per year.

<span class="mw-page-title-main">HIV/AIDS in Canada</span>

HIV/AIDS was first detected in Canada in 1982. In 2018, there were approximately 62,050 people living with HIV/AIDS in Canada. It was estimated that 8,300 people were living with undiagnosed HIV in 2018. Mortality has decreased due to medical advances against HIV/AIDS, especially highly active antiretroviral therapy (HAART).

<span class="mw-page-title-main">Cannabis in Australia</span> Recreational and medicinal drug use

Cannabis is a plant used in Australia for recreational, medicinal and industrial purposes. In 2019, 36% of Australians over the age of fourteen years had used cannabis in their lifetime and 11.6% had used cannabis in the last 12 months.

Michael Cowley FTSE is an Australian physiologist. He is best known for his mapping of the neural circuits involved in metabolism and obesity and diabetes treatment. He is a professor in the Department of Physiology at Monash University in the Faculty of Biomedical and Psychological Sciences. He is also a director of the Australian diabetes drug development company, Verva Inc, and director of the Monash Obesity & Diabetes Institute] (modi).

<span class="mw-page-title-main">Federal Ministry of Health (Nigeria)</span>


The Federal Ministry of Health is one of the Federal Ministries of Nigeria concerned with the formulation and implementation of policies related to health. It is headed by two Ministers appointed by the President, assisted by a Permanent Secretary, who is a career civil servant. The current Minister of Health is Muhammad Ali Pate. The current Minister of State for Health is Tunji Alausa. The Federal Ministry Of Health has over 800 workers consisting of closely 430 women and 370 men.[5]

<span class="mw-page-title-main">Dronabinol</span> Generic name of Δ9-THC in medicine

The International Nonproprietary Name dronabinol, also known under the trade names Marinol, Syndros, Reduvo and Adversa, is a generic name for the molecule of delta-9-tetrahydrocannabinol in the pharmaceutical context. It has indications as an appetite stimulant, antiemetic, and sleep apnea reliever and is approved by the FDA as safe and effective for HIV/AIDS-induced anorexia and chemotherapy-induced nausea and vomiting only.

<span class="mw-page-title-main">GW Pharmaceuticals</span>

GW Pharmaceuticals Limited is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols which was the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018. It is a subsidiary of Jazz Pharmaceuticals.

<span class="mw-page-title-main">Cannabis in Sweden</span> Use of cannabis in Sweden

Cannabis in Sweden is illegal for all purposes. It is illegal for recreational purposes, for most medical purposes and possession of even small amounts of cannabis is a criminal offence. Consequently, limited medical usage of cannabis-based drugs is only allowed for specific conditions.

<span class="mw-page-title-main">21st Century Cures Act</span> Bill enacted by the 114th United States Congress

The 21st Century Cures Act is a United States law enacted by the 114th United States Congress in December 2016 and then signed into law on December 13, 2016. It authorized $6.3 billion in funding, mostly for the National Institutes of Health. The act was supported especially by large pharmaceutical manufacturers and was opposed especially by some consumer organizations.

References

  1. 1 2 3 4 "Cannabis acceptance up in smoke - NDARC in collaboration with Pfizer A - Cannabis Research - Cannabis Community". Cannabis.community.forums.ozstoners.com. Retrieved 9 December 2016.
  2. 1 2 "World-first study into cannabis withdrawal management drug | NCPIC". Archived from the original on 1 April 2015.{{cite web}}: CS1 maint: unfit URL (link)
  3. Melissa Davey (3 November 2016). "Coalition will not renew cannabis research centre funding past 2016 | Australia news". The Guardian. Retrieved 9 December 2016.
  4. Australian Institute of Health and Welfare. (2010). 2010 National Drug Strategy Household Survey: first results. Canberra: AIHW.
  5. "Questions for Jan Copeland and the NCPIC - Page 6 - Australian Cannabis Politics and Activism - Cannabis Community". Cannabis.community.forums.ozstoners.com. 3 May 2011. Retrieved 9 December 2016.
  6. Fogarty, Siobhan (4 November 2016). "Cannabis addiction support centre to close doors after government cuts funding". ABC News. Retrieved 7 March 2017.